Clinical Trial Update: Romidepsin in Treating Patients With Relapsed Small Cell Lung Cancer [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update for romidepsin in relapsed small cell lung cancer; the study has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Small Cell Lung Cancer

Drugs mentioned

• Istodax (romidepsin)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Recurrent Small Cell Lung Cancer | Phase 2 | Status: COMPLETED